Exelixis Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenues: Approximately $629 million, including $573 million from the cabozantinib (cabo) franchise.

CABOMETYX Revenues: $571 million, with $2.7 million from clinical trial sales.

Gross to Net Deductions: 29.5%, lower than Q1 2026 due to reduced co-pay assistance, with a full-year estimate now projected between 30% and 31%.

Operating Expenses: Approximately $380 million, up from $359 million in Q1 2026, driven by increased clinical trial costs and marketing expenses.

Net Income: GAAP net income of $212 million ($0.85 per share) and non-GAAP net income of $237 million ($0.95 per share).

Cash and Marketable Securities: Approximately $1.4 billion.

Share Repurchase: $312 million spent to repurchase about 6.5 million shares at an average price of $47.85.

2Strategic Updates and Business Highlights

Pipeline Development: Exelixis is transitioning from a single compound focus to a multi-franchise oncology business, with Zanzalintinib (zanza) as a key growth driver.

Zanza Trials: Seven pivotal trials are ongoing or imminent, with a focus on colorectal cancer (CRC) and neuroendocrine tumors (NET).

Cabo Growth: The cabo franchise continues to perform well, with a year-over-year revenue growth of 10% in Q2 2026.

Market Share: CABOMETYX holds over 45% market share in the second-line plus NET segment and remains the leading TKI for renal cell carcinoma (RCC).

3Forward Guidance and Outlook

Revenue Guidance: Total revenues and net product revenue guidance for 2026 have been lowered by $50 million due to slower growth in the NET indication.

R&D Expense Guidance: Reduced by $50 million, reflecting a disciplined approach to capital allocation while investing in key R&D priorities.

Zanza Launch: Anticipated regulatory review for zanza in third-line plus CRC is set for December 2026, with preparations underway for its potential launch.

4Bad News, Challenges, or Points of Concern

Slower Growth: The growth trajectory for the NET indication is more gradual than initially expected, attributed to the unique characteristics of the NET patient population.

Gross to Net Deductions: A decrease in gross to net deductions could impact future revenue projections.

Competitive Pressures: Potential competition from new therapies in the market could affect CABOMETYX's market share and growth.

Regulatory Uncertainty: Ongoing reviews and the potential for label limitations could constrain the uptake of zanza if approved.

5Notable Q&A Insights

STELLAR-304 Timing: Expected data readout in the second half of 2026, but no specific timelines were provided for presentation at medical meetings.

Patient Kinetics in NET: The slow patient flow to subsequent therapies in NET is acknowledged, with the potential impact on cabo sales noted.

Market Dynamics: There is optimism about increasing market share in the community setting for CABOMETYX, with a strong promotional focus.

Zanza's Competitive Position: Zanza is positioned to potentially be the first oral agent in NET, with excitement among key opinion leaders (KOLs) regarding its trials.

Concerns on Subgroup Analysis: Questions arose about the non-liver mets subgroup in the STELLAR-303 study, with the company noting statistical insignificance in that subgroup while emphasizing the overall population data. Overall, Exelixis remains focused on executing its strategic initiatives while navigating challenges in revenue growth and market competition. The upcoming regulatory decisions and trial results will be critical for the company's future trajectory.